Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene

Pituitary

Volumn 8, Issue 2, 2005, Pages 115-122

  Geer, Eliza B ^a   Landman, Rita E ^a   Wardlaw, Sharon L ^a   Conwell, Irene M ^a   Freda, Pamela U ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Hypothalamic Pituitary Adrenal axis; Nalmefene; Opioid antagonist

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; NALMEFENE; OPIATE ANTAGONIST;

ADULT; ARTICLE; BODY MASS; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN TEST; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DYSPNEA; ENDOCRINE FUNCTION TEST; FATIGUE; FEMALE; GOLD STANDARD; HEADACHE; HEART PALPITATION; HORMONE DEFICIENCY; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNORADIOMETRIC ASSAY; MALE; METHODOLOGY; NAUSEA AND VOMITING; NORMAL HUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RADIOIMMUNOASSAY; RISK ASSESSMENT; STRESS; YAWNING;

ADRENOCORTICOTROPIC HORMONE; ADULT; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PITUITARY-ADRENAL SYSTEM; STIMULATION, CHEMICAL;

EID: 33644513148     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-005-5227-6     Document Type: Article

References (44)

1. Oelkers W. Adrenal insufficiency. New Engl J Med 1996;335:1206-1212.
2. Grinspoon S, Biller B. Laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab 1994;79:923-931.
3. Ammari F, Issa B, Millward E, Scanion M. A comparison between short ACTH and insulin stress tests for assessing hypothalamic-pituitary-adrenal function. Clin Endocrinol 1996;44:473-476.
4. Hagg E, Asplund K, Lithner F. Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency. Clinical Endocrinology 1987;26:221-226.
5. Taylor T, Dluhy RG, Williams GH. B-endorphin suppresses adrenocorticoptropin and cortisol levels in normal human subjects. J Clin Endocrinol Metab 1983;57:592-595.
6. Rittmaster RS, Cutler GB J, Sobel DO, et al. Morphine inhibits the pituitary-adrenal response to ovine corticotropin-releasing hormone in normal subjects. J Clin Endocrinol Metab 1985;60:891-895.
7. Grossman A, Gaillard RC, McCartney P, Rees LH, Besser GM. Opiate modulation of the pituitary-adrenal axis: Effects of stress and circadian rhythm. Clinical Endocrinology 1982;17:279-286.
8. Volavka J. Short-term hormonal effects of naloxone in man. Psychoneuroendocrinology 1980;5:225-234.
9. Morley J, Barnetsky N, Wingert T, et al. Endocrine effects of naloxone-induced opiate receptor blockade. J Clin Endocrinol Metab 1980;50:251-257.
10. Plotsky P. Opioid Inhibition of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation of rats. Regulatory Peptides 1986;16:235-242.
11. Nikolarakis K, Pfeiffer A, Stalla G, Herz A. The role of CRF in the release of ACTH by opiate agonists and antagonists in rats. Brain Research 1987;421:373-376.
12. Blevins L, Dobs A, Wand G. Naloxone-induced activation of the hypothalamic-pituitary-adrenal axis in suspected central adrenal insufficiency. Am J Med Sci 1994;308(3):167-170.
13. Nye E, Hockings G, Grice J, Strakosch C, Torpy D, Jackson R. The use of naloxone for investigating disorders of the hypothalamic-pituitary-adrenal axis. The Endocrinologist 1999;9:161-182.
14. Schluger J, Ho A, Borg L, et al. Nalmefene causes greater hypothalamic-pituitary adrenal axis activation than naloxone in normal volunteers: Implications for the treatment of alcoholism. Alcohol Clin Exp Res 1998;22(7):1430-1436.
15. Schultz C, Rivers E, Feldkamp C. A characterization of hypothalamic-pituitary-adrenal axis function during and after human cardiac arrest. Crit Care Med 1993;21:1339-1347.
16. Allen J, Cook D, Olsen J. Effect of insulin induced hypoglycemia on ACTH, cortisol, and growth hormone release in man. Mil Med 1975;12:837-840.
17. Raff H, Findling J. A new immunoradiometric assy for corticotropin evaluated in normal subjects and patients with cushings syndrome. Clin Chem 1989;35:596-600.
18. Harrison B, Lesley H, Cayton R, Nabarro J. Recovery of hypothalamic-pituitary-adrenal function in asthmatics whose oral steroids have been stopped or reduced. Clin Endocrinol (Oxf) 1982;17:109-118.
19. Streck W, Lockwood A. Pituitary adrenal recovery following short term suppression with corticosteroids. Am J Med 1979;66:910-914.
20. Hjortrup A, Kehlet H, Lindholm J, Stentoft P. Value of 30-minute adrenocorticotropin (ACTH) test in demonstrating hypothalamic-pituitary-adrenocortical insufficiency after acute ACTH deprivation. J Clin Endocrinol Metab 1983;57:668-670.
21. Dickstein G, Shechner C, Nicholson WE, et al. Adrenocorticotropin stimulation test: Effects of basal cortisol level, time of day, and suggested new sensitive low dose test. J Clin Endocrinol Metab 1991;72:773-778.
22. Talwar V, Lodha S, Dash RJ. Assessing the hypothalamo-pituitary-adrenocortical axis using physiological doses of adrenocorticotropic hormone. Q J Med 1998;91:285-290.
23. Rose SR, Lustig RH, Burstein S, Pitukcheewanont P, Broome DC, Burghen GA. Diagnosis of ACTH deficiency comparison of overnight metyrapone test to either low-dose or high-dose ACTH test. Horm Res 1999;52:73-79.
24. Weintrob N, Sprecher E, Josefsberg Z, et al. Standard and low-dose short adrenocorticotropin test compared with insulin-induced hypoglycemia for assessment of the hypothalamic-pituitary-adrenal axis in children with idiopathic multiple pituitary hormone deficiencies. J Clin Endocrinol Metab 1998;83(1):88-92.
25. Mayenknecht J, Diederich S, Bahr V, Plockinger U, Oelkers W. Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. J Clin Endocrinol Metab 1998;83(5):1558-1562.
26. Nye EJ, Grice JE, Hockings GI, et al. Adrenocorticotropin stimulation tests in patients with hypothalamic-pituitary disease: Low dose, standard high dose and 8-h infusion tests. Clinical Endocrinology 2001;55:625-633.
27. Abdu TAM, Elhadd TA, Neary R, Clayton RN. Comparison of the low dose short synacthen test (I ug), the conventional dose short synacthen test (250 ug), and the insulin tolerance test for the assessment of the hypothalamic-pituitary-adrenal axis in patients with pituitary disease. J Clin Endocrinol Metab 1999;84:838-843.
28. Suliman AM, Smith TP, Labib M, Fiad TM, McKenna TJ. The low-dose ACTH test does not provide a useful assessment of the hypothalamic-pituitary-adrenal axis in secondary adrenal insufficiency. Clinical Endocrinology 2002;56:533-539.
29. Orth DN, Jackson RV, DeCherney GS, et al. Effect of synthetic ovine corticotropin-releasing factor dose response of plasma adrenocorticotropin and cortisol. J Clin Invest 1983;71:587-595.
30. Schulte HM, Chrousos GP, Avgerinos P, et al. The cortico-tropin-releasing hormone stimulation test: A possible aid in the evaluation of patients with adrenal insufficiency. J Clin Endocrinol Metab 1984;58(6):1064-1067.
31. Schlaghecke R, Kornely E, Santen RT, Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992;326(4):226-230.
32. Delitala G, Trainer P, Oliva O, Fanciulli G, Grossman A. Opioid peptide and alpha-adrenoceptor pathways in the regulation of the pituitary-adrenal axis in man. J Endocrinol 1994;141:163-168.
33. Zis AP, Haskett RF, Albala AA, Carroll BJ. Morphine inhibits cortisol and stimulates prolactin secretion in man. Psychoneuroendocrinology 1984;9(4):423-427.
34. Inder W, Ellis M, Evans M, Donald R. A comparison of the naloxone test with ovine CRH and insulin hypoglycemia in the evaluation of the hypothalamic-pituitary-adrenal axis in normal man. Clin Endocrinol 1995;43:425-431.
35. McAllister A, McCance D, Hadden D, et al. A comparison of the naloxone test with the insulin stress test in patients following transphenoidal surgery. Clin Endocrinol 1999;50:261-265.
36. Product Information: REVEX (R), nalmefene. New Providence, NJ: Baxter Pharmaceutical Products, 1999.
37. Michel ME, Bolger G, Weissman BA. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 1985;7:175-177.
38. Erturk E, Jaffe C, Barkan A. Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test. J Clin Endocrinol Metab 1998;83:2350-2354.
39. Kaplan J, Marx J, Calabro J, et al. Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose. Ann Emerg Med 1999;34:42-50.
40. Mason B, Ritvo E, Morgan R, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res. 1994;18(5):1162-1167.
41. Ward R, Lawrence R, Hawkins R, DiChiara S, Biegner A, Vacchiano C. The use of nalmefene for intrathecal opioid-associated nausea in postpartum patients. AANA J 2002;70(1):57-60.
42. Clark W, Raps E, Tong D, Kelly R. Cervene (nalmefene) in acute ischemic stroke: Final results of a phase III efficacy study. Stroke 2000;31:1234-1239.
43. Mason B, Salvato F, Williams L, Rivto E, Cutler R. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999;56(8):719-724.
44. McArthur J, Turnbull B, Pehrson J, et al. Nalmefene enhances LH secretion in a proportion of oligo-amenorrheic athletes. Acta Endocrinologica 1993;128:325-333.